| 庄大洁,吴立平.信迪利单抗药物不良反应及文献分析[J].中国药事,2023,(1):102-108 |
| 信迪利单抗药物不良反应及文献分析 |
| Adverse Drug Reactions and Literature Analysis of Sintilimab |
| |
| DOI：10.16153/j.1002-7777.2023.01.012 |
| 中文关键词: 信迪利单抗 文献分析 药品不良反应 心肌损害 糖尿病 |
| 英文关键词: sintilimab literture analysis adverse drug reaction myocardial injury diabetes |
| 基金项目: |
|
| 摘要点击次数: 1114 |
| 全文下载次数: 949 |
| 中文摘要: |
| 目的：分析信迪利单抗发生药品不良反应(ADR)的情况和临床特征，为临床安全用药提供参考。方法：对中国知网、万方、维普、PubMed数据库中关于信迪利单抗相关不良反应的个案进行整理和分析。结果：共获得信迪利单抗相关的文献23篇，总计23例，其中60~69岁的患者发生ADR的人数最多 (34.78%)，ADR的高发时间段为用药后的1~30 d(39.13%)，最常累及的是内分泌系统(16.22%)， 其次是消化系统(13.51%)，大多数患者经积极治疗后可好转，少数患者因各种并发症而死亡。结论： 临床在使用信迪利单抗时应加强对患者的监测，避免不良反应的发生，增加用药安全性。 |
| 英文摘要: |
| Objective: To analyze the occurrence and clinical characteristics of adverse drug reactions (ADRs) induced by Sintilimab, and provide reference for clinical safe medication. Methods: The cases of ADRs induced by Sintilimab which were collected from CNKI, Wanfang, VIP database and PubMed were summarized and analyzed. Results: A total of 23 literatures related to Sintilimab were obtained, with a total of 23 cases. Patients aged 60-69 years had the most ADR (34.78%), and the high incidence period of ADR is 1-30 days after medication (39.13%), the endocrine system was most commonly involved (16.22%), followed by digestive system (13.51%). The most of patients could get better after active treatment, a small number of patients died from various complications of the disease. Conclusion: Clinical use of Sintilimab should strengthen the monitoring of ADR detection, in order to avoid the occurrence of adverse reactions and increase drug safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |